Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00847197 | A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) | PHASE2 | COMPLETED | 191 | — | — | Jun 1, 2008 | Sep 1, 2009 | Dec 21, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MK1903 |
| 2 | PLACEBO_COMPARATOR | Placebo to MK1903 |
| Name | Type | Description |
|---|---|---|
| MK1903 | DRUG | Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period. |
| Comparator: Placebo | DRUG | Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period. |
Inclusion Criteria: * Participant is not on a statin or other lipid-modifying therapy * Low or moderate risk participant * Male participants, and female participants not of reproductive potential Exclusion Criteria: * Female participant of reproductive potential * Participant is pregnant, breastf...